DISPLAY The development of therapeutic antibodies is a trajectory that moves from identification to optimization. While initial screening campaigns often yield binders with reasonable specificity, early-stage candidates rarely possess the picomolar affinity or sub-nanomolar potency required for clinical efficacy. This … Continue reading →